There are healthcare rollups that chase scale, and then there are platforms that actually understand anatomy, incentives, and gravity. Curalta Foot & Ankle just secured a growth investment led by SharpVue Capital, and this is not about fresh dollars chasing logos. This is pressure applied precisely where outcomes, ops, and patient trust intersect. Foot and ankle care sits at the crossroads of chronic disease, mobility, aging populations, and quality of life. Ignore it and everything else limps.
Founded in 2021 by David Del Vecchio and Vincent Giacalone, DPM, FACFAS, Curalta Foot & Ankle went after a podiatry market that had been fragmented, undercapitalized, and operationally uneven for decades. Today the platform spans 70+ clinical locations across NY, NJ, and PA, supported by 100+ board-certified specialists. That footprint is not accidental. It is what happens when clinicians buy into systems that respect medicine and operators build rails that actually work.
SharpVue Capital stepping in alongside NewSpring Capital, BPEA Private Equity, North Haven Capital, and Bluwave Capital signals conviction getting deeper, not broader. The mandate is clean. Expand across the Northeast, invest in specialty services from advanced surgery to wound care and sports medicine, and keep building infrastructure that lets providers focus on care while the platform handles scale. Growth capital only compounds when the engine is already tuned.
Burt Rubin did not arrive guessing. With real experience scaling complex healthcare platforms and managing serious P&L, Burt Rubin brought operational discipline without draining culture. That balance matters when roughly 90% of associates hold equity and think like owners. It shows up in retention, smoother integrations, and a workforce that understands the long game.
Clinical leadership here is not ceremonial. Jeffrey Gewirtz, DPM oversees quality and outcomes. Oren K. Isacoff, MD, MBA aligns growth strategy with clinical reality. Vincent Giacalone, DPM, FACFAS drives Curalta Clinical Trials, turning research into a real innovation channel instead of a brochure bullet. When research, ops, and care delivery actually communicate, results stop being theoretical.
The connective tissue is tech. ModMed standardizes documentation, coding, billing, imaging, and analytics across dozens of locations without flattening physician autonomy. Fewer denials, faster collections, cleaner data. In healthcare, boring efficiency is lethal in the best way.
Curalta Foot & Ankle is not trying to be loud. It is trying to be durable. This round tightens the laces on a platform built for distance, not headlines. For independent podiatrists, it is a partnership path that respects autonomy. For patients, it is coordinated care that does not feel fragmented. For investors, it is what disciplined healthcare growth actually looks like when the foundation can carry the weight.
Startups Startup Funding Venture Capital Podiatry Pediatric Care Healthcare Health Tech Infrastructure Data Data Driven Technology Innovation Tech Ecosystem Startup Ecosystem
